Xeris Biopharma Holdings, Inc.
XERSDrugs in Pipeline
12
Phase 3 Programs
4
Upcoming Catalysts
1
Next Catalyst
Aug 6, 2026
TomorrowMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
XERS Earnings Report
EPS Est: $0.02 | FQ end 2026-06 | Call: 2026-08-06 15:00:00
How XERS's past catalysts played out
Glucagon
Diabetes Mellitus, Type 1
G-Pen (glucagon injection)
Hypoglycemia
G-Pen
Insulin Hypoglycemia
Lilly Glucagon
Insulin Hypoglycemia
Glucagon RTU
Hyperinsulinemic Hypoglycemia
Glucagon RTU Injection With Insulin Pump Reduction
Hypoglycemia
G-Pen Mini™ (glucagon injection)
Hypoglycemia
PRAM9
Diabetes Mellitus, Type 1
G-Pen(TM) 1 mg
Hypoglycemia
Novo Nordisk GlucaGen®
Hypoglycemia
levothyroxine sodium
Hypothyroidism
G-Pump™ (glucagon infusion)
Hypoglycemia
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Glucagon | Phase 3 | Diabetes Mellitus, Type 1 | - | - |
G-Pen (glucagon injection) | Phase 3 | Hypoglycemia | - | - |
G-Pen | Phase 3 | Insulin Hypoglycemia | - | - |
Lilly Glucagon | Phase 3 | Insulin Hypoglycemia | - | - |
Glucagon RTU | Phase 2 | Hyperinsulinemic Hypoglycemia | - | - |
Glucagon RTU Injection With Insulin Pump Reduction | Phase 2 | Hypoglycemia | - | - |
G-Pen Mini™ (glucagon injection) | Phase 2 | Hypoglycemia | - | - |
PRAM9 | Phase 2 | Diabetes Mellitus, Type 1 | - | - |
G-Pen(TM) 1 mg | Phase 2 | Hypoglycemia | - | - |
Novo Nordisk GlucaGen® | Phase 2 | Hypoglycemia | - | - |
levothyroxine sodium | Phase 2 | Hypothyroidism | - | - |
G-Pump™ (glucagon infusion) | Phase 2 | Hypoglycemia | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Xeris Biopharma Holdings, Inc.'s drug pipeline?→
CatalystAlert tracks 12 drug candidates in Xeris Biopharma Holdings, Inc.'s (XERS) pipeline across Phase 3, Phase 2. Its lead program is Glucagon (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Xeris Biopharma Holdings, Inc.'s next FDA catalyst?→
Xeris Biopharma Holdings, Inc.'s (XERS) next tracked catalyst is a Earnings expected August 6, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track XERS biotech catalysts?→
Add XERS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Xeris Biopharma Holdings, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.